CN103450167A - 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途 - Google Patents
一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途 Download PDFInfo
- Publication number
- CN103450167A CN103450167A CN201210167607XA CN201210167607A CN103450167A CN 103450167 A CN103450167 A CN 103450167A CN 201210167607X A CN201210167607X A CN 201210167607XA CN 201210167607 A CN201210167607 A CN 201210167607A CN 103450167 A CN103450167 A CN 103450167A
- Authority
- CN
- China
- Prior art keywords
- oxadiazole
- pyrazine
- preparation
- hydrazides
- washing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003373 pyrazinyl group Chemical group 0.000 title claims abstract description 18
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 64
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 98
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 27
- 238000005406 washing Methods 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000004821 distillation Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 6
- 235000015320 potassium carbonate Nutrition 0.000 claims description 6
- 238000000967 suction filtration Methods 0.000 claims description 6
- 150000005072 1,3,4-oxadiazoles Chemical class 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 150000003935 benzaldehydes Chemical class 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- TWIIRMSFZNYMQE-UHFFFAOYSA-N methyl pyrazine-2-carboxylate Chemical class COC(=O)C1=CN=CC=N1 TWIIRMSFZNYMQE-UHFFFAOYSA-N 0.000 claims description 3
- 229940072033 potash Drugs 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 2
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 4
- 206010006187 Breast cancer Diseases 0.000 abstract description 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 2
- 206010017758 gastric cancer Diseases 0.000 abstract description 2
- 208000010749 gastric carcinoma Diseases 0.000 abstract description 2
- 201000005202 lung cancer Diseases 0.000 abstract description 2
- 208000020816 lung neoplasm Diseases 0.000 abstract description 2
- 201000000498 stomach carcinoma Diseases 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 37
- -1 alkaloid compound Chemical class 0.000 description 32
- 239000000843 powder Substances 0.000 description 29
- IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- FYKZHAJQLBLBJO-UHFFFAOYSA-N 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]propan-2-ol Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C=C(C=CC=2)C=2OC(C)=NN=2)CC1 FYKZHAJQLBLBJO-UHFFFAOYSA-N 0.000 description 2
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- MULPYFRDYRZMDS-UHFFFAOYSA-N Tiodazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=NN=C(SC)O1 MULPYFRDYRZMDS-UHFFFAOYSA-N 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 229950007126 nesapidil Drugs 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229950000282 tiodazosin Drugs 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- SUYSQRHNTDVWKJ-UHFFFAOYSA-N 1,3-dichlorobenzene;formaldehyde Chemical compound O=C.ClC1=CC=CC(Cl)=C1 SUYSQRHNTDVWKJ-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- CMWKITSNTDAEDT-UHFFFAOYSA-N 2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC=C1C=O CMWKITSNTDAEDT-UHFFFAOYSA-N 0.000 description 1
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 1
- JHZOXYGFQMROFJ-UHFFFAOYSA-N 3,5-dibromo-2-hydroxybenzaldehyde Chemical compound OC1=C(Br)C=C(Br)C=C1C=O JHZOXYGFQMROFJ-UHFFFAOYSA-N 0.000 description 1
- FABVMBDCVAJXMB-UHFFFAOYSA-N 3,5-dichloro-2-hydroxybenzaldehyde Chemical compound OC1=C(Cl)C=C(Cl)C=C1C=O FABVMBDCVAJXMB-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
- MKKSTJKBKNCMRV-UHFFFAOYSA-N 5-bromo-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Br)C=C1C=O MKKSTJKBKNCMRV-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- YOWVEYCZVUOQAB-SOFGYWHQSA-N Furamizole Chemical compound O1C(N)=NN=C1C(\C=1OC=CC=1)=C\C1=CC=C([N+]([O-])=O)O1 YOWVEYCZVUOQAB-SOFGYWHQSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- VWKZUKLWZAKHCB-UHFFFAOYSA-N NNC(CSc1nnc(-c2nccnc2)[o]1)=O Chemical compound NNC(CSc1nnc(-c2nccnc2)[o]1)=O VWKZUKLWZAKHCB-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 238000009333 weeding Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
技术领域
本发明涉及一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途。
背景技术。
1,3,4-噁二唑衍生物具有广泛的生物活性,如:杀菌、杀虫、抗炎、抗癌等,广泛应用于医药、农药等领域。由于1,3,4-噁二唑便于人体代谢,且其结构有利于氢键的形成,故其常被用做为有效的药效基团。有三种上市药物含1,3,4-噁二唑结构,其中,奈沙地尔(Nesapidil)和Furamizole是抗高血压药物,硫达唑嗪(Tiodazosin)是一种抗生素。
吡嗪环是一种重要的化学骨架,已上市的很多药物中都含有吡嗪环结构,例如吡嗪酰胺对结核杆菌具有很好的杀灭作用;格列吡嗪是一种很好的降血糖药等。研究发现一些含有吡嗪环的衍生物具有一定的抗结核杆菌、抗炎、抗癌等活性。
酰腙类化合物是的一类特殊的Schiff碱类化合物,比普通的Schiff碱化合物稳定。近年来研究发现含有-CONHN=CH-基团的酰腙类化合物具有较高的杀菌、消炎、除草、抗病毒等生物活性,某些酰腙类化合物还具有抗癌作用,因此在医药、农药等方面受到了广泛的关注。
因此,本发明设计的化合物引入不同的具有一定药物活性的化学骨架,可能有助于提高化合物的抗癌活性,是很好的课题。
发明内容
本发明的目的在于提供一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物以及它们的制备方法与用途。
本发明的技术方案如下:
一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物,其特征是它有如下通式:
式中R为:
一种制备上述的含1,3,4-噁二唑和吡嗪环的酰腙类衍生物的方法,其特征是它由下列步骤组成:
步骤1.将0.1mol 2-吡嗪羧酸溶于50ml甲醇,置于带有回流装置的圆底烧瓶中,缓慢滴入2.5ml浓硫酸,在60℃下回流反应4h。
步骤2.减压蒸馏除去甲醇,20ml乙酸乙酯溶解,饱和食盐水洗涤3次除去浓硫酸,减压蒸馏除去乙酸乙酯得无色透明油状2-吡嗪羧酸甲酯。
步骤3.加入20ml乙醇,15ml水合肼,80℃回流2小时。冷却至室温,析出大量白色固体,抽滤,少量乙醇洗涤,干燥得白色固体2-吡嗪酰肼。
步骤4.将步骤3中得到的2-吡嗪酰肼溶于100ml甲醇中,0.2mol的氢氧化钠,25ml水,20ml二硫化碳,60℃回流24h。反应结束后减压蒸馏除去二硫化碳和甲醇,然后加入稀盐酸,调PH至7,析出淡黄色固体,抽滤,水洗3次,乙醇洗涤1次,烘干。
步骤5.将步骤4所得淡黄色固体溶于50ml丙酮,加入1个当量的无水碳酸 钾,1个当量的溴乙酸乙酯,60℃回流4h。反应结束后过滤除去碳酸钾固体,用丙酮洗涤碳酸钾3次,洗涤液倒入滤液,旋干,得白色固体。
步骤6.将步骤5所得白色固体溶于50ml乙醇,加入15ml水合肼,冰浴搅拌12h,析出白色固体,过滤,水洗一次,乙醇洗一次,得含有1,3,4-噁二唑环的酰肼。
步骤7.将1mmol步骤6所得的酰肼溶于5ml乙醇,加入1mmol取代苯甲醛和3滴乙酸,常温搅拌5h,析出大量白色固体,过滤,乙醇洗涤3次,烘干,得含有1,3,4-噁二唑环酰腙类化合物。
实验结果表明,本发明的新型含有1,3,4-噁二唑和吡嗪环的酰腙类衍生物对人肺癌细胞A549,人肝癌细胞HepG2,人乳腺癌细胞MCF7和人胃癌细胞SGC7901具有明显的抑制作用。因此本发明的含有1,3,4-噁二唑和吡嗪环的酰腙类衍生物可以应用于制备抗癌药物。
具体实施方式
通过以下实施例进一步详细说明本发明,但本发明的范围并不受这些实施例的任何限制。
实施例一:(2-(5-(吡嗪-2-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼的制备
将0.1mol 2-吡嗪羧酸溶于50ml甲醇,置于带有回流装置的圆底烧瓶中,缓慢滴入2.5ml浓硫酸,在60℃下回流反应4h。减压蒸馏除去甲醇,20ml乙酸乙酯溶解,饱和食盐水洗涤3次除去浓硫酸,减压蒸馏除去乙酸乙酯得无色透明油状2-吡嗪羧酸甲酯。加入20ml乙醇,15ml水合肼,80℃回流1小时。冷却至室温,析出大量白色固体,抽滤,少量乙醇洗涤,干燥得白色固体2-吡嗪酰肼。将得到的2-吡嗪酰肼溶于100ml甲醇中,0.2mol的氢氧化钠,25ml水,20ml二 硫化碳,60℃回流24h。反应结束后减压蒸馏除去二硫化碳和甲醇,然后加入稀盐酸,调PH至7,析出淡黄色固体,抽滤,水洗3次,乙醇洗涤1次,烘干。将所得淡黄色固体溶于50ml丙酮,加入1个当量的无水碳酸钾,1个当量的溴乙酸乙酯,60℃回流4h。反应结束后过滤除去碳酸钾固体,用丙酮洗涤碳酸钾3次,洗涤液倒入滤液,旋干,得白色固体。将所得白色固体溶于50ml乙醇,加入15ml水合肼,冰浴搅拌12h,析出白色固体,过滤,水洗一次,乙醇洗一次,得含有1,3,4-噁二唑环的酰肼。白色粉末,产率54%.m.p.184-185℃;1H NMR(300MHz,DMSO-d6):2.02(s,2H),4.72(s,2H),7.89-7.91(m,2H),8.75(s,1H),11.84(s,1H).MS(ESI):253.04(C8H9N6O2S,[M+H]).Anal.Calcd for C8H8N6O2S:C,38.09;H,3.20;N,33.32%.Found:C,38.17;H,3.21;N,33.35%.
实施例二:(E)-N′-苄基-2-((5-(吡嗪-2-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物1)的制备
将实施例一中所得酰肼1mmol溶于5ml乙醇,加入1mmol苯甲醛,3滴乙酸,室温下反应4h,析出白色固体。过滤,烘干,得到目标化合物。白色粉末,产率82%,m.p.175-176℃;1H NMR(300MHz,DMSO-d6):5.24(s,2H),7.89(m,3H),8.21(s,2H),8.60(s,1H),9.24-9.26(m,2H),9.78(s,1H),11.12(s,1H).MS(ESI):341.07(C15H13N6O2S,[M+H]+).Anal.Calcd for C15H12N6O2S:C,52.93;H,3.55;N,24.69%.Found:C,52.80;H,3.56;N,19.20%.
实施例三:(E)-N′-(4-氟苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物2)的制备
制备方法同实施例二。以4-氟苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率80%,m.p.214-215℃;1H NMR(300MHz,DMSO-d6):4.69(s,2H),7.24-7.28(m,1H),7.74-7.79(m,2H),7.87-7.90(m,2H),8.04(s,1H),8.78-8.81(m,2H),11.78(s,1H).MS(ESI):359.06(C15H12FN6O2S,[M+H]+).Anal.Calcd for C15H11FN6O2S:C,50.27;H,3.09;N,23.45%.Found:C,50.37;H,3.10;N,23.47%.
实施例四:(E)-N′-(4-溴苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物3)的制备
制备方法同实施例二。以4-溴苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率86%,m.p.196-197℃;1H NMR(300MHz,DMSO-d6):4.67(s,2H),7.24-7.27(m,1H),7.74-7.76(m,2H),7.88-7.91(m,2H),8.05(s,1H),8.79-8.82(m,2H),11.77(s,1H).MS(ESI):418.98(C15H12BrN6O2S,[M+H]+).Anal.Calcd for C15H11BrN6O2S:C,42.97;H,2.64;N,20.05%.Found:C,42.850;H,2.63;N,20.09%.
实施例五:(E)-N′-(4-硝基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物4)的制备
制备方法同实施例二。以4-硝基苯甲醛代替苯甲醛,得到目标化合物。黄色粉末,产率81%,m.p.234-235℃;1H NMR(300MHz,DMSO-d6):4.74(s,2H),7.96-7.98(m,2H),8.15(s,1H),8.25-8.27(m,1H),8.36-8.38(m,1H),8.84-8.86(m,2H),9.30-9.33(d,J=9.33,1H),12.09(s,1H).MS(ESI):386.06(C15H12N7O4S,[M+H]+).Anal.Calcd for C15H11N7O4S:C,46.75;H,2.88;N,25.44%.Found:C,46.65;H,2.88;N,25.40%.
实施例六:(E)-N′-(4-羟基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物5)的制备
制备方法同实施例二。以4-羟基苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率84%,m.p.156-157℃;1H NMR(300MHz,DMSO-d6):4.67(s,2H),6.79-6.83(m,2H),7.51-7.53(m,2H),7.94(s,1H),8.85-8.87(m,2H),9.30(s,1H),9.90(s,1H),11.61(s,1H).MS(ESI):357.07(C15H13N6O3S,[M+H]+).Anal.Calcd for C15H12N6O3S:C,50.56;H,3.39;N,23.58%.Found:C,50.44;H,3.39;N,23.62%.
实施例七:(E)-N′-(4-甲氧基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物6)的制备
制备方法同实施例二。以4-甲氧基苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率86%,m.p.239-240℃;1H NMR(300MHz,DMSO-d6):3.79(s,3H),4.67(s,2H),6.97-7.06(m,2H),7.62-7.66(m,1H),7.87-7.91(m,2H),7.98(s,1H),8.78-8.81(m,2H),11.66(s,1H).MS(ESI):357.07(C16H15N6O3S,[M+H]+).Anal.Calcd for C16H14N6O3S:C,51.88;H,3.81;N,22.69%.Found:C,51.74;H,3.80;N,22.62%.
实施例八:(E)-N′-(3-氟苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物7)的制备
制备方法同实施例二。以3-氟苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率82%,m.p.194-195℃;1H NMR(300MHz,DMSO-d6):4.71(s,2H),7.21-7.27(m,1H),7.43-7.56(m,3H),8.03(s,1H),8.84-8.86(m,2H),9.30-9.32(d,J=7.14,1H),11.90(s,1H).MS(ESI):359.07(C15H12FN6O2S,[M+H]+).Anal.Calcd for C15H11FN6O2S:C,50.27;H,3.09;N,23.45%.Found:C,50.31;H,3.08;N,23.44%.
实施例九:(E)-N′-(3-氯苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物8)的制备
制备方法同实施例二。以3-氯苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率81%,m.p.192-193℃;1H NMR(300MHz,DMSO-d6):4.73(s,2H),7.21-7.24(m,1H),7.46-7.53(m,3H),8.04(s,1H),8.84-8.86(m,2H),9.31-9.33(d,J=7.14,1H),11.92(s,1H).MS(ESI):375.04(C15H12ClN6O2S,[M+H]+).Anal.Calcd for C15H11ClN6O2S:C,48.07;H,2.96;N,22.42%.Found:C,48.17;H,2.95;N,22.45%.
实施例十:(E)-N′-(3-溴苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物9)的制备
制备方法同实施例二。以3-溴苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率82%,m.p.182-183℃;1H NMR(300MHz,DMSO-d6):4.73(s,2H),7.24-7.27(m,1H),7.48-7.55(m,3H),8.04(s,1H),8.85-8.87(m,2H),9.31-9.33(d,J=7.14,1H),11.93(s,1H).MS(ESI):418.99(C15H12BrN6O2S,[M+H]+).Anal.Calcd for C15H11BrN6O2S:C,42.94;H,2.64;N,20.05%.Found:C,42.81;H,2.65;N,20.10%.
实施例十一:(E)-N′-(3-硝基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物10)的制备
制备方法同实施例二。以3-硝基苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率83%,m.p.224-225℃;1H NMR(300MHz,DMSO-d6):4.74(s,2H),7.22-7.26(m,1H),7.47-7.55(m,3H),8.01(s,1H),8.83-8.85(m,2H),9.31-9.33(d,J=7.14,1H),11.94(s,1H).MS(ESI):386.06(C15H12N7O4S,[M+H]+).Anal.Calcd for C15H11N7O4S:C,46.75;H,2.88;N,25.44%.Found:C,46.68;H,2.86;N,25.49%.
实施例十二:(E)-N′-(2-羟基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物11)的制备
制备方法同实施例二。以3-羟基苯甲醛代替苯甲醛,得到目标化合物。制备方法同实施例二。以间羟基苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率84%,m.p.174-176℃;1H NMR(300MHz,DMSO-d6):4.68(s,2H),6.81-6.92(m,2H),7.21-7.31(m,1H),7.68-7.71(d,J=7.68,1H),7.87-7.90(m,2H),8.44(s,1H),8.78-8.81(t,J=4.41,2H),10.03(s,1H),11.71(s,1H).MS(ESI):357.07(C15H13N6O3S,[M+H]+).Anal.Calcd for C15H12N6O3S:C,50.56;H,3.39;N,23.58%.Found:C,50.47;H,3.38;N,23.55%.
实施例十三:(E)-N′-(3-(三氟甲基)苄基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物12)的制备
制备方法同实施例二。以3-三氟甲基苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率83%,m.p.160-161℃;1H NMR(300MHz,DMSO-d6):4.74(s.2H),7.66-7.70(m,1H),7.76-7.79(t,J=5.04,1H),8.01-8.04(m,2H),8.13(s,1H),8.83-8.88(m,2H),9.29-9.33(d,J=7.77,1H),11.96(s,1H).MS(ESI):409.07(C16H12F3N6O2S,[M+H]+).Anal.Calcd for C16H11F3N6O2S:C,47.06;H,2.72;N,20.58%.Found:C,47.16;H,2.73;N,20.53%.
实施例十四:(E)-N′-(3-甲氧基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物13)的制备
制备方法同实施例二。以3-甲氧基苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率79%,m.p.166-167℃;1H NMR(300MHz,DMSO-d6):3.79(s,3H),4.67(s,1H),6.97-7.06(m,2H),7.62-7.66(m,2H),7.87-7.91(m,2H),7.98(s,1H),8.78-8.81(m,2H),11.66(s,1H).MS(ESI):371.09(C16H15N6O3S,[M+H]+).Anal.Calcd for C16H14N6O3S:C,51.88;H,3.81;N,22.69%.Found:C,51.78;H,3.82;N,22.79%.
实施例十五:(E)-N′-(2-氟苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物14)的制备
制备方法同实施例二。以2-氟苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率84%,m.p.170-171℃;1H NMR(300MHz,DMSO-d6):4.71(s,2H),7.25-7.30(m,2H),7.47-7.48(m,1H),7.86-7.93(m,1H),8.25(s,1H),8.84-8.86(m,2H),9.30-9.33(d,J=7.5,1H),11.91(s,1H).MS(ESI):359.07(C15H12FN6O2S,[M+H]+).Anal.Calcd for C15H11FN6O2S:C,50.27;H,3.09;N,23.45%.Found:C,50.37;H,3.08;N,23.43%.
实施例十六:(E)-N′-(2-氯苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物15)的制备
制备方法同实施例二。以2-氯苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率85%,m.p.189-190℃;1H NMR(300MHz,DMSO-d6):4.72(s,2H),7.25-7.30(m,2H),7.46-7.48(m,1H),7.87-7.92(m,1H),8.23(s,1H),8.85-8.87(m,2H),9.31-9.34(d,J=7.5,1H),11.93(s,1H).MS(ESI):375.04(C15H12ClN6O2S,[M+H]+).Anal.Calcd for C15H11ClN6O2S:C,48.07;H,2.96;N,22.42%.Found:C,48.17;H,2.97;N,22.48%.
实施例十七:(E)-N′-(2-溴苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物16)的制备
制备方法同实施例二。以2-溴苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率88%,m.p.199-200℃;1H NMR(300MHz,DMSO-d6):4.72(s,2H),7.24-7.30(m,2H),7.47-7.49(m,1H),7.88-7.92(m,1H),8.23(s,1H),8.85-8.87(m,2H),9.30-9.32(d,J=7.5,1H),11.93(s,1H).MS(ESI):418.99(C15H11BrN6O2S,[M+H]+).Anal.Calcd for C15H11BrN6O2S:C,42.97;H,2.64N,20.05%.Found:C,42.91;H,2.65;N,20.09%.
实施例十八:(E)-N′-(2-硝基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物17)的制备
制备方法同实施例二。以2-硝基苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率85%,m.p.224-225℃;1H NMR(300MHz,DMSO-d6):4.71(s,2H),7.25-7.30(m,2H),7.47-7.48(m,1H),7.86-7.93(m,1H),8.25(s,1H),8.84-8.86(m,2H),9.30-9.33(d,J=7.5,1H),11.91(s,1H).MS(ESI):386.06(C15H12N7O4S,[M+H]+).Anal.Calcd for C15H11N7O4S:C,46.75;H,2.88;N,25.44%.Found:C,46.83;H,2.89;N,25.40%.
实施例十九:(E)-N′-(2-羟基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物18)的制备
制备方法同实施例二。以水杨醛代替苯甲醛,得到目标化合物。白色粉末,产率84%,m.p.164-165℃;1H NMR(300MHz,DMSO-d6):4.71(s,2H),6.85-6.88(m,2H),7.37-7.43(m,2H),7.84(s,1H),7.88-7.89(m,2H),8.27(s,1H),8.78-8.79(d,J=3.12,1H),11.79(s,1H).MS(ESI):357.06(C15H13N6O3S,[M+H]+).Anal.Calcd for C15H12N6O3S:C,50.56;H,3.39;N,23.58%.Found:C,50.44;H,3.39;N,23.60%.
实施例二十:(E)-N′-(5-氯-2-羟基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物19)的制备
制备方法同实施例二。以5-氯水杨醛代替苯甲醛,得到目标化合物。制备方法同实施例二。以5-氯水杨醛代替苯甲醛,得到目标化合物。白色粉末,产率83%,m.p.198-199℃;1H NMR(300MHz,DMSO-d6):4.71(s,2H),6.85-6.88(m,2H),7.37-7.43(m,1H),7.84(s,1H),7.88-7.89(m,2H),8.27(s,1H),8.78-8.79(d,J=3.12,1H),11.79(s,1H).MS(ESI):391.03(C15H12ClN6O3S,[M+H]+).Anal.Calcd for C15H11ClN6O3S:C,46.10;H,2.84;N,21.50%.Found:C,46.19;H,2.85;N,21.55%.
实施例二十一:(E)-N′-(5-溴-2-羟基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物20)的制备
制备方法同实施例二。以5-溴水杨醛代替苯甲醛,得到目标化合物。白色粉末,产率82%,m.p.208-209℃;1H NMR(300MHz,DMSO-d6):4.71(s,2H),6.85-6.88(m,2H),7.37-7.43(m,2H),7.84(s,1H),7.88-7.89(m,1H),8.27(s,1H),8.78-8.79(d,J=3.12,1H),11.79(s,1H).MS(ESI):434.98(C15H12BrN6O3S,[M+H]+).Anal.Calcd for C15H11BrN6O3S:C,41.39;H,2.55;N,19.31%.Found:C,41.29;H,2.55;N,19.35%.
实施例二十二:(E)-N′-(3,5-二氯-2-羟基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物21)的制备
制备方法同实施例二。以3,5-二氯水杨醛代替苯甲醛,得到目标化合物。白色粉末,产率81%,m.p.194-195℃;1H NMR(300MHz,DMSO-d6):4.73(s,2H),6.86-6.89(m,2H),7.39-7.42(m,1H),7.85(s,1H),7.88-7.89(m,1H),8.28(s,1H),8.78-8.80(d,J=3.12,1H),11.78(s,1H).MS(ESI):425.00(C15H11Cl2N6O3S,[M+H]+).Anal.Calcd for C15H10Cl2N6O3S:C,42.37;H,2.37;N,19.76%.Found:C,42.39;H,2.37;N,19.78%.
实施例二十三:(E)-N′-(3,5-二溴-2-羟基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物22)的制备
制备方法同实施例二。以3,5-二溴水杨醛代替苯甲醛,得到目标化合物。白色粉末,产率85%,m.p.204-205℃;1H NMR(300MHz,DMSO-d6):4.74(s,2H),6.85-6.87(m,2H),7.38-7.42(m,1H),7.85(s,1H),7.87-7.89(m,1H),8.28(s,1H),8.77-8.79(d,J=3.12,1H),11.77(s,1H).MS(ESI):512.89(C15H11Br2N6O3S,[M+H]+).Anal.Calcd for C15H10Br2N6O3S:C,31.08;H,1.96;N,16.35%.Found:C,31.15;H,1.97;N,16.38%。
实施例二十四:(E)-N′-(3,4-二羟基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物23)的制备
制备方法同实施例二。以原儿茶醛代替苯甲醛,得到目标化合物。白色粉末,产率82%,m.p.213-214℃;1H NMR(300MHz,DMSO-d6):4.66(s,2H),6.75-6.76(m,1H),6.91(s,1H),7.16-7.18(m,1H),7.86(s,1H),8.85-8.86(m,2H),9.23(s,1H),9.31-9.32(m,1H),9.40(s,1H),11.57(s,1H).MS(ESI):373.07(C15H13N6O4S,[M+H]+).Anal.Calcd for C15H12N6O4S:C,48.38;H,3.25;N,22.57%.Found:C,48.30;H,3.24;N,22.58%.
实施例二十五:(E)-N′-(4-羟基-3-甲氧基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物24)的制备
制备方法同实施例二。以香草醛代替苯甲醛,得到目标化合物。白色粉末,产率85%,m.p.154-155℃;1H NMR(300MHz,DMSO-d6):3.79(s,3H),4.66(s,2H),6.99-7.06(m,2H),7.62-7.65(m,1H),7.87-7.90(m,2H),7.98(s,1H),8.79-8.81(m,2H),11.67(s,1H).MS(ESI):387.08(C16H15N6O4S,[M+H]+).Anal.Calcd for C16H14N6O4S:C,49.74;H,3.65;N,21.75%.Found:C,49.79;H,3.64;N,21.78%.
实施例二十六:(E)-N′-(2,4-二氯甲氧基苯甲亚基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物25)的制备
制备方法同实施例二。以2,4-二氯苯甲醛代替苯甲醛,得到目标化合物。白色粉末,产率86%,m.p.184-185℃;1H NMR(300MHz,DMSO-d6):4.69(s,2H),7.47-7.49(m,1H),7.69-7.72(d,J=6.24,1H),7.85-7.86(d,J=3.48,2H),7.97-7.99(d,J=5.04,1H),8.36(s,1H),8.79(s,1H),11.99(s,1H).MS(ESI):409.00(C15H11Cl2N6O2S,[M+H]+).Anal.Calcd for C15H10Cl2N6O2S:C,44.02;H,2.46;N,20.54%.Found:C,44.15;H,2.45;N,20.59%.
实施例二十七:(E)-N′-(呋喃-2-亚甲基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物26)的制备
制备方法同实施例二。以糠醛代替苯甲醛,得到目标化合物。白色粉末,产率86%,m.p.190-191℃;1H NMR(300MHz,DMSO-d6):4.71(s,2H),7.43-7.45(m,2H),7.69-7.71(m,2H),7.88-7.91(m,1H),8.06(s,1H),8.79-8.82(m,1H),11.81(s,1H).MS(ESI):331.06(C13H11N6O3S,[M+H]+).Anal.Calcd for C13H10N6O3S:C,47.27;H,3.05;N,25.44%.Found:C,47.35;H,3.06;N,25.39%.
实施例二十八:(E)-N′-(噻吩-2-亚甲基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物27)的制备
制备方法同实施例二。以噻吩-2-甲醛代替苯甲醛,得到目标化合物。白色粉末,产率86%,m.p.211-212℃;1H NMR(300MHz,DMSO-d6):4.73(s,2H),7.42-7.44(m,2H),7.68-7.70(m,1H),7.87-7.90(m,1H),8.06(s,1H),8.78-8.81(m,2H),11.82(s,1H).MS(ESI):347.04(C13H11N6O2S2,[M+H]+).Anal.Calcd for C13H10N6O2S2:C,45.08;H,2.91;N,24.26%.Found:C,45.18;H,2.92;N,24.30%.
实施例二十九:(E)-N′-((E)-3-苯烯丙叉基)-2-((5-(吡嗪-4-基)-1,3,4-噁二唑-2-基)硫代)丙酮酰肼(化合物28)的制备
制备方法同实施例二。以肉桂醛代替苯甲醛,得到目标化合物。淡黄色粉末,产率82%,m.p.207-208℃;1H NMR(300MHz,DMSO-d6):5.1(s,2H),7.38-7.51(m,2H),7.79-7.86(m,4H),8.03-8.04(d,J=4.41,2H),8.38(s,1H),9.25(m,3H),11.00(s,1H).MS(ESI):367.09(C17H15N6O2S,[M+H]+).Anal.Calcd for C17H14N6O2S:C,55.73;H,3.85;N,22.94%.Found:C,55.76;H,3.83;N,22.90%。
Claims (3)
2.一种制备权利要求1所述的含1,3,4-噁二唑和吡嗪环的酰腙类衍生物的方法,其特征是它由下列步骤组成:
步骤1.将0.1mol 2-吡嗪羧酸溶于50ml甲醇,置于带有回流装置的圆底烧瓶中,缓慢滴入2.5ml浓硫酸,在60℃下回流反应4h。
步骤2.减压蒸馏除去甲醇,20ml乙酸乙酯溶解,饱和食盐水洗涤3次除去浓硫酸,减压蒸馏除去乙酸乙酯得无色透明油状2-吡嗪羧酸甲酯。
步骤3.加入20ml乙醇,15ml水合肼,80℃回流1小时。冷却至室温,析出大量白色固体,抽滤,少量乙醇洗涤,干燥得白色固体2-吡嗪酰肼。
步骤4.将步骤3中得到的2-吡嗪酰肼溶于100ml甲醇中,0.2mol的氢氧化钠,25ml水,20ml二硫化碳,60℃回流24h。反应结束后减压蒸馏除去二硫化碳和甲醇,然后加入稀盐酸,调PH至7,析出淡黄色固体,抽滤,水洗3次,乙醇洗涤1次,烘干。
步骤5.将步骤4所得淡黄色固体溶于50ml丙酮,加入1个当量的无水碳酸钾,1个当量的溴乙酸乙酯,60℃回流4h。反应结束后过滤除去碳酸钾固体,用丙酮洗涤碳酸钾3次,洗涤液倒入滤液,旋干,得白色固体。
步骤6.将步骤5所得白色固体溶于50ml乙醇,加入15ml水合肼,冰浴下搅拌12h,析出白色固体,过滤,水洗一次,乙醇洗一次,得含有1,3,4-噁二唑环的酰肼。
步骤7.将1mmol步骤6所得的酰肼溶于5ml乙醇,加入1mmol取代苯甲醛和3滴乙酸,常温搅拌5h,析出大量白色固体,过滤,乙醇洗涤3次,烘干,得含有1,3,4-噁二唑环酰腙类化合物。
3.权利要求1所述的含1,3,4-噁二唑和吡嗪环的酰腙类衍生物在制备抗癌药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210167607XA CN103450167A (zh) | 2012-05-28 | 2012-05-28 | 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210167607XA CN103450167A (zh) | 2012-05-28 | 2012-05-28 | 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103450167A true CN103450167A (zh) | 2013-12-18 |
Family
ID=49733053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210167607XA Pending CN103450167A (zh) | 2012-05-28 | 2012-05-28 | 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103450167A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105936827A (zh) * | 2015-12-16 | 2016-09-14 | 南开大学 | 一种盘状1,3,4-噁二唑类室温液晶二聚体及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1436179A (zh) * | 2000-04-21 | 2003-08-13 | 盐野义制药株式会社 | 具有抗癌作用的噁二唑衍生物 |
-
2012
- 2012-05-28 CN CN201210167607XA patent/CN103450167A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1436179A (zh) * | 2000-04-21 | 2003-08-13 | 盐野义制药株式会社 | 具有抗癌作用的噁二唑衍生物 |
Non-Patent Citations (1)
Title |
---|
RAKESH R. SOMANI ET AL.: "Investigation of 1, 3, 4-oxadiazole scaffold as potentially active compounds", 《INTERNATIONAL JOURNAL OF DRUG DESIGN AND DISCOVERY》, vol. 2, no. 1, 31 March 2011 (2011-03-31), pages 353 - 360 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105936827A (zh) * | 2015-12-16 | 2016-09-14 | 南开大学 | 一种盘状1,3,4-噁二唑类室温液晶二聚体及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ramesh et al. | Synthesis and biological evaluation of new rhodanine analogues bearing 2-chloroquinoline and benzo [h] quinoline scaffolds as anticancer agents | |
CN105732468B (zh) | 一种n’-(2-(1h-吲哚-3-基)乙酰基)芳酰肼类化合物及其制备方法和用途 | |
CN103739594A (zh) | 一类含吡嗪环和三氮唑结构的席夫碱类衍生物及其制法 | |
Esmaili et al. | Synthesis of novel pyrimido [4, 5-b] quinolines containing benzyloxy and 1, 2, 3-triazole moieties by DABCO as a basic catalyst | |
CN103450167A (zh) | 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途 | |
CN103044284A (zh) | 香草酸酰腙类衍生物及其制备和用途 | |
CN103012347B (zh) | 尿素酶抑制剂黄酮氧肟酸类化合物及其制法和用途 | |
CN103113355B (zh) | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 | |
CN103373992A (zh) | 一类含1,3,4-噁二唑和吡啶(吡嗪)环的酰腙类衍生物及其制备方法与用途 | |
CN102775381B (zh) | 取代的酰肼类化合物及其制备方法、药物组合物和用途 | |
CN106866707A (zh) | 一种苯并咪唑并[2,1‑b]噻唑衍生物的制备方法 | |
CN103450168A (zh) | 一类含1,3,4-噁二唑和吡啶的酰腙类衍生物及其制备方法与用途 | |
CN106243089B (zh) | 4位含查尔酮结构单元的6-取代-2-(苯并咪唑-2-亚甲硫基)嘧啶类化合物及其制备方法和用途 | |
CN102127067B (zh) | 2-(6-氨基苯并噻唑-2-巯基)-乙酰胺衍生物及其制备方法和用途 | |
CN102775389B (zh) | N-取代-4-(7-氯喹啉-4-氨基)-苯甲酰胺衍生物的制备方法和应用 | |
CN103373988A (zh) | 一类含1,2,4-三氮唑和吡嗪环的酰腙类衍生物及其制备方法与用途 | |
CN112679409B (zh) | 一种4-吲哚-取代硫半脲衍生物及其制备方法和应用 | |
CN110272412A (zh) | 一种酞嗪酮衍生物及其制备方法和医药用途 | |
CN104003987B (zh) | 他克林-β-咔啉异二连体类多功能胆碱酯酶抑制剂 | |
CN108530438B (zh) | 一种苯并噻唑-噁唑型α-葡萄糖苷酶抑制剂及其制备方法和应用 | |
CN101434601B (zh) | 一种2-呋喃基-1h-苯并咪唑-4-酰胺型衍生物 | |
CN103058982A (zh) | 含卤素取代的联苯双酯衍生物、制备方法及其用途 | |
CN105712988B (zh) | 一种2‑氨基‑4,5‑二芳基噻唑型化合物及其制法和用途 | |
CN103304584B (zh) | 一类2-腙-噻唑并[4,5-b]喹喔啉类化合物及其制法与用途 | |
CN104119319A (zh) | 含1,2,3-三氮唑和脲结构单元的嘧啶衍生物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131218 |